Osteoporosis Drugs Linked to Lower Alzheimer's and Dementia Risk in Study

Commonly used osteoporosis drugs, specifically nitrogen-containing bisphosphonates (NBP), have been associated with a reduced risk of developing Alzheimer's disease and other forms of dementia, according to a significant study involving over 121,000 older adults. The findings, published in Alzheimer’s & Dementia, indicate that individuals taking NBPs showed a 16% lower risk of Alzheimer's and related dementias compared to those not using osteoporosis medications.

The study also found a 24% lower risk for patients on NBPs compared to those taking other types of osteoporosis medications. Nitrogen-containing bisphosphonates, which include common drugs like alendronate, ibandronate, risedronate, and zoledronate, are primarily prescribed to slow bone loss and decrease fracture risk, particularly in individuals with osteoporosis.

Osteoporosis, a condition characterized by weakened bones and increased fracture susceptibility due to bone mass loss, is prevalent among older populations. The research focused on adults aged 60 and older in Hong Kong who had recently been diagnosed with osteoporosis or experienced a major fracture and had not previously taken osteoporosis medication.

Researchers noted a potential connection between bone health and brain health, suggesting a 'bone-brain axis.' Previous research has indicated that individuals with low bone mass or osteoporosis may face a higher risk of developing dementia later in life. This connection underscores the importance of maintaining good bone health for potentially mitigating dementia risk.

However, the study authors emphasized that their findings are based on observational data and do not establish a cause-and-effect relationship. "Our findings therefore do not prove that bisphosphonate use reduces dementia risk; this needs confirmation in a clinical trial," stated study author Ching-Lung Cheung, associate professor at the University of Hong Kong’s Li Ka Shing Faculty of Medicine.

Limitations of the study include its focus on a single population group, raising questions about the generalizability of the findings to other ethnic groups. Additionally, the absence of baseline cognitive testing meant that individuals who already had cognitive impairment might have been less likely to be prescribed osteoporosis treatments. Information regarding the severity of osteoporosis, fracture history, and the use of calcium and vitamin D supplements was also not available.

External factors such as education level, social isolation, air pollution, and vision loss were acknowledged as potential influences on dementia risk. While the study suggests a correlation, the authors cautioned against prescribing bisphosphonates solely for the prevention or treatment of Alzheimer's disease based on these results.

Further research, including clinical trials with diverse populations and consideration of gender-specific effects, is recommended to validate these findings. "The next step is to confirm our observational findings in a clinical trial," Cheung said. "If the benefit is demonstrated, it could have important implications for dementia management." The researchers hope their findings will prompt patients and healthcare professionals to consider the overall benefits and risks of appropriate treatments when indicated.